

Product Catalog

Your partner for human molecular diagnostics



Genetic Disorder



Genetic Predisposition



Cancer



Pharmacogenetics



Microbiology

Sample Preparation Kits













| Area | Product Name | REF | Reg. Status | Unit Size | Application |
|----------------------------------|---|-------|-------------|-----------|---|
| StripAssays® RealFast™ Assays | GENxTRACT™ Blood DNA Extraction System | 2-014 | CE/IVD | 100 Rxn | DNA extraction from fresh, frozen and dried blood |
| StripAssays® RealFast™ Assays | Spin Micro DNA Extraction Kit | 2-020 | RUO | 20 Rxn | DNA extraction and purification from whole blood and buccal swabs |
| RealFast™ Assays | D2PCR™ Buffer | 2-030 | CE/IVD | 100 Rxn | For direct-to-PCR applications |


Workflow of RealFast™ Assays











RealFast™ Assays

Single marker detection






| Category | Clinical Topic | Product Name | REF 100 / 32 Rxn | Reg. Status | Description |
|---|--------------------------------------|-------------------------------|------------------|-------------|---|
|  | Carbamazepine Hypersensitivity | HLA-A3101 RealFast™ Assay | 7-640 / 7-643 | CE/IVD | Detects the human leukocyte antigen (HLA) <i>HLA-A*31:01</i> allele, which is strongly associated with carbamazepine hypersensitivity reactions in Europeans and Japanese |
|  | Carbamazepine Hypersensitivity | HLA-B1502 RealFast™ Assay | 7-630 / 7-633 | CE/IVD | Detects the human leukocyte antigen (HLA) <i>HLA-B*15:02</i> allele, which is strongly associated with carbamazepine hypersensitivity reactions in Asian populations |
|  | Carbohydrate Intolerance | LCT -13910C>T RealFast™ Assay | 7-150 / 7-153 | CE/IVD | Detects the most common polymorphism in the <i>lactase (LCT)</i> gene causing lactase non-persistence |
|  | Cardiovascular Diseases (CVD) | FGB -455G>A RealFast™ Assay | 7-230 / 7-233 | CE/IVD | Identifies homozygosity for the -455G>A <i>fibrinogen beta-chain (FGB)</i> allele which may increase susceptibility to atherothrombosis in at-risk patients |
|  | CVD | FV Leiden RealFast™ Assay | 7-110 / 7-113 | CE/IVD | Detects the most common genetic risk factor associated with venous thromboembolism, the 1691G>A mutation in the <i>Factor V (FV)</i> gene |
|  | CVD | FXII 46C>T RealFast™ Assay | 7-240 / 7-243 | CE/IVD | Identifies patients with the unfavorable TT genotype for <i>Factor XII (FXII)</i> , who may have an increased susceptibility to thrombotic disorders |
|  | CVD | FXIII V34L RealFast™ Assay | 7-250 / 7-253 | CE/IVD | Identifies carriers of the protective 34L variant of Factor XIII (FXIII) among at-risk patients of hereditary thrombophilia |
|  | CVD | MTHFR 677C>T RealFast™ Assay | 7-160 / 7-163 | CE/IVD | Detects common mutation in the <i>methylenetetrahydrofolate reductase (MTHFR)</i> gene causing hyperhomocysteinemia, which is a risk factor for cardiovascular disease |
|  | CVD | MTHFR 1298A>C RealFast™ Assay | 7-170 / 7-173 | CE/IVD | Detects common mutation in the <i>methylenetetrahydrofolate reductase (MTHFR)</i> gene causing hyperhomocysteinemia, which is a risk factor for cardiovascular disease |
|  | CVD | PAI-1 4G/5G RealFast™ Assay | 7-180 / 7-183 | CE/IVD | Detects the 4G risk allele in the <i>SERPINE1</i> gene, encoding plasminogen activator inhibitor-1 (PAI-1), and is associated with cardiovascular disease and pregnancy complications |
|  | CVD | PTH 20210G>A RealFast™ Assay | 7-120 / 7-123 | CE/IVD | Detects the second most important genetic risk factor for venous thromboembolism in the <i>Factor II</i> gene, encoding prothrombin (PTH) |
|  | Congenital Adrenal Hyperplasia (CAH) | CAH RealFast™ CNV Assay | 7-410 / --- | CE/IVD | Discriminates between deletions, duplications and normal copy number status of the <i>CYP21A2</i> gene in patients with CAH. Recommended to be used in combination with CAH StripAssay® [REF 4-380] |



RealFast™ Assays

| Category | Clinical Topic | Product Name | REF 100 / 32 Rxn | Reg. Status | Description |
|--|------------------------|---------------------------------|------------------|-------------|--|
|  | Genetic Predisposition | HLA-B*27 RealFast™ Assay | 7-620 / 7-23 | CE/IVD | Detects the human leukocyte antigen (HLA) <i>HLA-B*27</i> allele, which is associated with ankylosing spondylitis |
|  | Haemochromatosis | HFE C282Y RealFast™ Assay | 7-130 / 7-133 | CE/IVD | Detects the common C282Y variant in the <i>HFE</i> gene causing hereditary haemochromatosis (HH) type 1 |
|  | Haemochromatosis | HFE H63D RealFast™ Assay | 7-140 / 7-143 | CE/IVD | Detects the common H63D variant in the <i>HFE</i> gene causing hereditary haemochromatosis (HH) type 1 |
| NEW!  | Pharmacogenetics | CYP2D6 RealFast™ CNV Assay | 7-420 / --- | CE/IVD | Discriminates between deletions, duplications and normal copy number status of the <i>CYP2D6</i> gene. Recommended to be used in combination with PGX-CYP2D6 XL StripAssay®[REF 4-770] |
|  | Pharmacogenetics | HLA-B*57:01 RealFast™ Assay | 7-610 / 7-613 | CE/IVD | Detects the human leukocyte antigen (HLA) <i>HLA-B*57:01</i> allele, which is associated with hypersensitivity to the anti-HIV drug abacavir |
|  | Pharmacogenetics | IL28B RealFast™ Assay | 7-200 / 7-203 | CE/IVD | Detects a dinucleotide frame-shift variant coding for interleukin 28B (IL28B) and helps to predict the therapeutic response in Hepatitis C Virus infected patients |
|  | Pharmacogenetics | SLCO1B1c.521T>C RealFast™ Assay | 7-210 / 7-213 | CE/IVD | Detects a variant in human <i>solute carrier organic anion transporter family member 1B1 (SLCO1B1)</i> gene in patients who are at higher risk for developing statin-induced myopathy |
|  | Pharmacogenetics | VKORC1 -1639G>A RealFast™ Assay | 7-190 / 7-193 | CE/IVD | Detects the most important polymorphism in the <i>Vitamin K Epoxide Reductase Complex 1 (VKORC1)</i> gene associated with interindividual dose requirements for oral anticoagulants |

Multiplex testing - save costs and sample material


| Category | Clinical Topic | Product Name | REF 100 / 32 Rxn | Reg. Status | Description |
|---|----------------------|--------------------------------|------------------|-------------|--|
|  | CVD | FV-PTH mpx RealFast™ Assay | 7-115 / 7-118 | CE/IVD | Simultaneous detection of the most important thrombophilic mutations 1691G>A in the <i>Factor V</i> gene and 20210G>A in the <i>Factor II</i> gene, encoding prothrombin (PTH) |
|  | CVD | MTHFR mpx RealFast™ Assay | 7-165 / 7-168 | CE/IVD | Simultaneous detection of the most common two mutations in the <i>MTHFR</i> gene: 677C>T and 1298A>C |
|  | AAT deficiency/ COPD | AAT mpx RealFast™ Assay | 7-265 / 7-268 | CE/IVD | Detects *S and *Z variants of the <i>SERPINA1</i> gene predisposing individuals to chronic obstructive pulmonary disease (COPD) and liver disease due to deficiency of alpha-1 antitrypsin (AAT) |
|  | Haemochromatosis | HFE mpx RealFast™ Assay | 7-135 / 7-138 | CE/IVD | Simultaneous detection of the two most common mutations in the <i>HFE</i> gene: H63D and C282Y |
|  | Pharmacogenetics | CYP2C9 mpx RealFast™ Assay | 7-225 / 7-228 | CE/IVD | Simultaneous detection of <i>CYP2C9</i> *2(c.430C>T) and <i>CYP2C9</i> *3(c.1075A>C) polymorphisms to determine the drug response of known targets, like S-warfarin or phenytoin |
| | Service | RealFast™ Confirmation Service | CS-045 | --- | Service to assist in establishing RealFast™ Assays as well as for performance monitoring |

COVID-19

| Category | Clinical Topic | Product Name | REF 100 / 500 Rxn | Reg. Status | Description |
|----------|------------------------|----------------------------|-------------------|-------------|---|
| | Respiratory Infections | SARS-CoV-2 RealFast™ Assay | 8-410 / 8-412 | CE/IVD | Detects the viral <i>N</i> and <i>RdRP/ORF1ab</i> genes and the human <i>ACTB</i> gene as internal control in a multiplex one-step RT-PCR |



Workflow of StripAssays®



StripAssays®



| Category | Clinical Topic | Product Name | REF | Reg. Status | Unit Size | Description |
|----------|--------------------------------------|---------------------------------|-------|-------------|-----------|--|
| | Alzheimer Disease | Apo E StripAssay® | 4-280 | CE/IVD | 20 tests | Detection of isoforms Apo E2, E3 and E4 |
| | Cancer | BRAF 600/601 StripAssay® | 5-560 | CE/IVD | 20 tests | Ultra-sensitive detection of 9 <i>BRAF</i> mutations in codons 600 and 601 |
| | Cancer | EGFR XL StripAssay® | 5-630 | CE/IVD | 20 tests | Ultra-sensitive detection of 30 <i>EGFR</i> mutations in exons 18/19/20/21 |
| | Cancer | FCGR StripAssay® | 5-670 | RUO | 20 tests | Detection of allelic variants of Fc gamma-Receptor 2A (H131R) and 3A (F158V) associated with response to IgG antibody therapy |
| | Cancer | KRAS XL StripAssay® | 5-680 | CE/IVD | 20 tests | Ultra-sensitive detection of 29 <i>KRAS</i> mutations in codons 12/13/59/60/61/117/146 |
| | Cancer | NRAS XL StripAssay® | 5-620 | CE/IVD | 20 tests | Ultra-sensitive detection of 22 <i>NRAS</i> mutations in codons 12/13/59/60/61/146 |
| | Carbohydrate Intolerance | Lactose Intolerance StripAssay® | 4-300 | CE/IVD | 20 tests | Detection of two <i>lactase</i> gene polymorphisms -13910T>C and -22018A>G |
| | Carbohydrate Intolerance | Sugar Intolerance StripAssay® | 4-310 | CE/IVD | 20 tests | Detection of two <i>lactase</i> gene polymorphisms and four <i>aldolase B</i> gene mutations |
| | Cardiovascular Diseases (CVD) | CVD StripAssay® | 4-240 | CE/IVD | 20 tests | Testing for 12 genetic variants associated with cardiovascular diseases |
| | CVD | CVD StripAssay® A | 4-370 | CE/IVD | 20 tests | Testing for 8 genetic variants predisposing to atherosclerosis |
| | CVD | CVD StripAssay® T | 4-360 | CE/IVD | 20 tests | Testing for 9 genetic variants predisposing to venous thromboembolism |
| | CVD | FV-PTH StripAssay® | 4-290 | CE/IVD | 20 tests | Detection of the <i>Factor V</i> Leiden and <i>Factor II</i> , encoding prothrombin (PTH), gene mutations |
| | CVD | FV-PTH-MTHFR StripAssay® | 4-260 | CE/IVD | 20 tests | Detection of the <i>Factor V</i> Leiden, <i>Factor II</i> , encoding prothrombin (PTH), and <i>MTHFR</i> gene mutations |
| | Congenital Adrenal Hyperplasia (CAH) | CAH StripAssay® | 4-380 | CE/IVD | 20 tests | Testing for 11 most prevalent <i>CYP21A2</i> mutations. Recommended to be used in combination with CAH RealFast™ CNV Assay [REF 7-410] |
| | Cystic Fibrosis (CF) | CF StripAssay® | 4-410 | CE/IVD | 10 tests | Detection of 34 common <i>CFTR</i> mutations and the IVS8 variants 5T/7T/9T |
| | CF | CF StripAssay® GER | 4-430 | CE/IVD | 10 tests | Detection of 31 common <i>CFTR</i> mutations |
| | CF | CF StripAssay® TUR | 4-420 | CE/IVD | 10 tests | Detection of 24 common <i>CFTR</i> mutations and the IVS8 variants 5T/7T/9T |
| | CF | CF StripAssay® EXT | 4-440 | CE/IVD | 10 tests | Detection of 38 common <i>CFTR</i> mutations and the IVS8 variants 5T/7T/9T |
| | Familial Mediterranean Fever (FMF) | FMF StripAssay® | 4-230 | CE/IVD | 20 tests | Detection of 12 <i>MEFV</i> gene mutations |


StripAssays®

| Category | Clinical Topic | Product Name | REF | Reg. Status | Unit Size | Description |
|--|------------------------|----------------------------------|--------|-------------|-----------|--|
|  | FMF | FMF-SAA1 StripAssay® | 4-390 | CE/IVD | 20 tests | Detection of 12 <i>MEFV</i> gene mutations and <i>SAA1</i> genotypes 1.1, 1.3 and 1.5 |
|  | Genetic Predisposition | HLA-B27 StripAssay® | 4-320 | CE/IVD | 20 tests | Detection of all disease-relevant <i>HLA-B*27</i> subtypes |
|  | Haemochromatosis | Haemochromatosis StripAssay® A | 4-220 | CE/IVD | 20 tests | Detection of 18 mutations: twelve <i>HFE</i> mutations, four <i>TFR2</i> mutations and two <i>FPN1</i> mutations |
|  | Haemochromatosis | Haemochromatosis StripAssay® B | 4-210 | CE/IVD | 20 tests | Detection of 3 <i>HFE</i> gene mutations: C282Y, H63D, S65C |
| NEW!  | Pharmacogenetics | PGX-5FU XL StripAssay® | 4-780 | CE/IVD | 20 tests | Detection of <i>DPYD</i> genetic variants HapB3, <i>DPYD*13</i> , <i>DPYD*2A</i> , p.D949V associated with toxicity of 5-fluorouracil therapy |
|  | Pharmacogenetics | PGX-CYP2C19 StripAssay® | 4-750 | CE/IVD | 20 tests | Testing for CYP2C19 variants *1, *2, *3, *4, *5, *6, *7, *8 and *17 |
| NEW!  | Pharmacogenetics | PGX-CYP2D6 XL StripAssay® | 4-770 | CE/IVD | 20 tests | Testing for CYP2D6 variants *1 - *12, *14, *15*, *17, *29, *35, *39, *40, *41, *58, *114. Recommended to be used in combination with CYP2D6 RealFast™ CNV Assay [REF 7-420]. |
|  | Pharmacogenetics | PGX-HIV StripAssay® | 4-710 | CE/IVD | 20 tests | Testing for genotypes associated with response to HIV highly active anti-retroviral therapy |
|  | Pharmacogenetics | PGX-Thrombo StripAssay® | 4-730 | CE/IVD | 20 tests | Testing for <i>CYP2C9</i> and <i>VKORC1</i> variants associated with anticoagulant dose requirements |
|  | Pharmacogenetics | PGX-TPMT StripAssay® | 4-740 | CE/IVD | 20 tests | Testing for <i>TPMT</i> variants *1, *2, *3A, *3B and *3C associated with response to thiopurine therapy |
|  | Thalassemia | α-Globin StripAssay® | 4-160 | CE/IVD | 10 tests | Detection of 21 common α-Globin gene mutations |
|  | Thalassemia | β-Globin StripAssay® MED | 4-130 | CE/IVD | 20 tests | Detection of 22 mutations covering >90% of β-Globin defects found in Mediterranean countries |
|  | Thalassemia | β-Globin StripAssay® IME | 4-140 | CE/IVD | 20 tests | Detection of 22 mutations covering >90% of β-Globin defects found in the Middle East and India |
|  | Thalassemia | β-Globin StripAssay® SEA | 4-150 | CE/IVD | 20 tests | Detection of 22 mutations covering >90% of β-Globin defects found in Southeast Asia |
|  | Thalassemia | β-Thal Modifier StripAssay® | 4-170 | CE/IVD | 20 tests | Testing for 5 polymorphisms associated with severity of β-Thalassemia |
| | Service | StripAssay® Confirmation Service | CS-042 | --- | --- | Service to assist in establishing StripAssays® as well as for performance monitoring |

Software





| Area | Product Name | REF | Reg. Status | Unit Size | Application |
|--------------|-----------------------|-------|-------------|-----------|---|
| StripAssays® | StripAssay® Evaluator | 6-100 | RUO | --- | Software for automated scanning of teststrips, interpretation, and archiving of results |








NGS Assays

Amplicon-based Assays

| Category | Clinical Topic | Product Name | REF | Reg. Status | Unit Size | Description |
|--|-----------------------|-----------------------------------|----------|-------------|-----------|--|
| W!  | Intestinal Microbiome | 16S Microbiome NGS Assay [16 rxn] | 9-131-16 | RUO | 16 Rxn | Targeted amplification of V3-V4 variable regions of the 16S rRNA gene incl. bioinformatic analysis and report generation for species-level classification of the human gut microbiome. |
|  | Intestinal Microbiome | 16S Microbiome NGS Assay [Set A] | 9-131 | RUO | 96 Rxn | Differs from [Set B] and [Set C] in indexing primers only. Multiplexing up to 288 samples. |
|  | Intestinal Microbiome | 16S Microbiome NGS Assay [Set B] | 9-132 | RUO | 96 Rxn | Differs from [Set A] and [Set C] in indexing primers only. Multiplexing up to 288 samples. |
|  | Intestinal Microbiome | 16S Microbiome NGS Assay [Set C] | 9-133 | RUO | 96 Rxn | Differs from [Set A] and [Set B] in indexing primers only. Multiplexing up to 288 samples. |

Hybridization capture-based Assays

| Category | Clinical Topic | Product Name | REF | Reg. Status | Unit Size | Description | |
|----------|---|-------------------|---|-------------|-----------|-------------|--|
| NEW! |  | Genetic Disorders | Clinical Exome Sequencing (CES) NGS Assay | 9-241 | RUO | (4x4) Rxn | All-in-one solution (library preparation, GENOVESA bioinformatic solution, genetic report generation) for detection of SNVs and InDels in 7500+ clinically relevant genes. Covers the whole coding sequence (CDS) of targeted genes. |
| NEW! |  | Cancer | Hereditary Cancer NGS Assay | 9-221 | RUO | 16 Rxn | All-in-one solution (library preparation, GENOVESA bioinformatic solution, genetic report generation) targeting the whole CDS of 31 genes. Allows detection of SNVs, InDels, and CNVs of the covered genes (e.g. <i>BRCA1</i> , <i>BRCA2</i> , <i>CDH1</i> ,...). |
| NEW! |  | Cancer | Somatic Mutations NGS Assay | 9-231 | RUO | 16 Rxn | All-in-one solution (library preparation, GENOVESA bioinformatic solution, genetic report generation) targeting the whole CDS of genes covered. Detects SNVs and InDels in 10 genes (e.g. <i>BRAF</i> , <i>EGFR</i> , <i>KRAS</i> , ...) and fusions in 3 genes (i.e. <i>ALK</i> , <i>RET</i> , <i>ROS1</i>). |

MANUFACTURER:



ViennaLab Diagnostics GmbH

Gaudenzdorfer Guertel 43-45

A-1120 Vienna, Austria

+43 1 812 0156

info@viennalab.com

www.viennalab.com

DISTRIBUTOR:

EN ISO 13485
July 2023